-
2024-519504-27-00
5
Relapsed Refractory Multiple Myeloma
-
2024-519986-23-00
5
The study will involve adult women and men from 16 French centers who
-
2024-520089-70-00
5
Cutaneous lupus erythematosus
-
2024-520391-10-01
5
Obstetrical Brachial Plexus Palsy
-
2025-520554-11-00
5
Cardiovascular Disease
-
2025-520632-42-00
5
axial or predominantly axial SpA with or without psoriasis
-
2025-520976-25-00
4
Relapsed/refractory multiple myeloma
-
2025-521037-86-00
5
Immune system diseases
-
2025-521038-27-00
5
Immune system diseases
-
2025-521039-35-00
5
Impact on delirium of the use of DEXmedetomidine as first-line sedati
-
2025-521090-14-00
4
Patients with relapsed/refractory symptomatic multiple myeloma (MM)
-
2025-521154-42-00
4
Sickle Cell Disease
-
2025-521199-80-00
4
Patients with previously untreated symptomatic chronic lymphocytic leu
-
2025-521322-14-00
4
Patients over 55 with Acute Myeloid Leukemia (AML) and IDH1 mutation,
-
2025-521331-36-00
10
Patient with stabilized SSc-ILD (as defined by a decline of FVC ≤ 5%)
-
2025-521371-31-00
4
Sepsis
-
2025-521478-32-00
5
PEDIATRIC ACUTE MYOCARDITIS
-
2025-521571-30-00
5
Young Adults and adults with R/R B-cell acute lymphoblastic leukemia (
-
2025-521587-35-00
5
Metastatic colorectal cancer
-
2025-521590-13-00
5
Moderately to Severely Active Crohn’s Disease
-
2025-521713-57-00
7
Noninfectious Uveitis
-
2025-522019-40-00
9
relapsed or refractory BCR::ABL1-positive (Philadelphia positive, Ph+)
-
2025-522339-32-00
9
Neoplasm malignant
-
2025-522475-28-00
5
Pulmonary Hypertension (PH) with Heart Failure with preserved left ven